Expanded sales force fuels market development. IRVINE, CA/ ACCESSWIRE/ January 12, 2023/ HippoFi, Inc. (previously ORHub), (OTC PINK: ORHB), a varied business concentrated on the biotech and fintech markets, launches 2023 with robust sales of its PUR Biologics line of items. “We have actually broadened our sales channels in the last 6 weeks by over 28% and expect this quick development to continue throughout the year. Consumer need is driving sales towards record highs as we constantly assist clients with our innovative biologic options. HippoFi’s Biotech department is well placed to be a leader in biologics with our PUR Biologics offering and appealing future innovations,” stated CJ Wiggins, Executive Chairman & CEO of HippoFi, Inc. “We are stimulated by the significant assistance and favorable feedback we are getting from our cosmetic surgeon clients, tactical partners, and supplier channels. This rapid success in sales represents a growing momentum to catch considerable market share over the next 12 months and is a credit to our impressive group and our special market relationships,” specified Ryan Fernan, Head of PUR Biologics. HippoFi is traded on the OTC under the sign “ORHB”. ### About HippoFi, Inc. HippoFi, Inc. provides its innovative health care developments through a comprehensive sales channel network while carrying out first-to-market services in the multibillion-dollar Biotech, Fintech, and Artificial Intelligence (AI) markets. HippoFi makes up 3 sections: Regenerative Therapeutics, Digital Payments, and AI, which make use of the exact same client channels to advertise options, drive profits, and enhance client results. PUR Biologics ®, HippoFi’s Regenerative Therapeutic department, uses a portfolio of ingenious biological items and exclusive innovations for bone development in surgical Spine treatments along with trademarked bioactive cellular matrix structures and advanced autologous cell treatments for restoring cartilage in joints and back discs. HippoFi-PayTM, the business’s Digital Payment department, runs a surgical implant and company management software application, which standardize procedures at the point of surgical care with enhanced logistics and effectiveness to supply medical gadget and biologic suppliers with HIPAA & NPI certified implant confirmation and faster payments. HippoFi’s AI department is focused particularly on making use of AI for early medical diagnosis and predictive modeling of Cancer and enhancing service choices particular to Spine surgical treatment. HippoFi, Inc. is openly traded under the sign: ORHB and is headquartered in Irvine, California. For more details, please check out: www.hippofi.com and www.PURbiologics.com Contact: Jason Brown Shareholder Communications 612-209-7565 SOURCE: HippoFi, Inc.
HippoFi Begins 2023 with Strong Sales of Advanced Biomaterials
